Weight Loss

NEW Insurance support for GLP-1s, check your eligibility today.

Weight Loss

$49 per visit, no subscription needed*. Select GLP-1s available for as little as $149/month for self-pay patients with a manufacturer’s savings card**. Check your eligibility today.

Introduction to GLP-1s for weight loss

  • Walgreens Weight Management can prescribe a variety of glucagon-like peptide-1 (GLP-1) agonist medications that may be appropriate. A doctor or nurse practitioner will assess whether a GLP-1 agonist medication is suitable for you, taking into account your individual health factors such as BMI and medical history, and will recommend the most appropriate medication for your needs. Today, Walgreens Weight Management can prescribe GLP-1 agonist medications such as semaglutide (Wegovy®), tirzepatide (Zepbound®), and orforglipron (Foundayo™).

    Wegovy®, Zepbound®, and Foundayo™ medication are all FDA-approved medications indicated for weight reduction and long-term weight maintenance in certain patients, but contain different active ingredients.

    • Wegovy is available as a daily oral pill and weekly injection with active ingredient semaglutide
    • Zepbound is a weekly injection with active ingredient tirzepatide
    • Foundayo is a daily oral pill with active ingredient orforglipron

    All of these medications belong to the GLP-1 agonist drug class. However, Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist.

  • Wegovy and Zepbound are both FDA-approved for weight loss and maintaining weight loss long term. Wegovy contains the active ingredient semaglutide, while Zepbound contains tirzepatide. Both medications:

    • Belong to the GLP-1 agonist drug class, but Zepbound medication (tirzepatide) also works as a GIP agonist, which further helps control blood sugar and improves fat storage and metabolism.
    • Are available as an injection. Wegovy is also available as a daily pill.
    • Are approved for use in adults aged 18 years and older. Although, Wegovy can also be used in adolescents as young as 12 years of age. Wegovy tablets are approved only for adults.

    Both Wegovy and Zepbound medication carry additional approvals beyond weight loss.

    • Wegovy is approved to lower the risk of major adverse cardiovascular events (MACE). Injectable Wegovy is also approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to severe liver fibrosis.
    • Zepbound medication is approved to treat moderate to severe obstructive sleep apnea in adults with obesity.

    The right choice for you depends on your health needs. A Walgreens Weight Management provider can help determine which medication may be appropriate for you.

  • Who is eligible for GLP-1 medications for weight loss?

    Generally, GLP-1 agonist medications for weight loss are FDA-approved for adults aged 18 years and older with certain body mass indexes (BMI) - typically a BMI of 30 or above, or a BMI of 27 or above if you have a weight-related health condition such as hypertension, high cholesterol, weight-related anxiety, liver disease, sleep apnea or PCOS. Individuals under 18 may be eligible for certain treatment options but need to talk with their health care provider. Please note, prescription is based on medical evaluation and is not guaranteed.

    For Medicare patients interested in the Medicare GLP-1 Bridge program, additional eligibility requirements may apply. Learn more and see if it may be right for you, here.

  • Virtual care makes it easier to get support on your weight loss journey, without the hassle of scheduling appointments, traveling to a doctor’s office, or paying for a subscription. With a Walgreens Weight Management visit, if eligible, you’ll meet with a doctor or nurse practitioner through video shortly after you request your first visit. Our providers will review your medical history, discuss your goals, and create a personalized treatment plan. Your care plan may include a prescription for a weight loss medication, if appropriate, along with monthly follow-ups with a provider for your first few months, which may vary based on your medication and individual needs, to check your progress and adjust your treatment as needed.

    Medicare patients can start or continue GLP-1 care through our Walgreens Medicare Weight Management visit. Click here for more details.

  • Like with all medications, patients who take GLP-1 medications for weight loss may experience side effects. Specific side effects vary depending on which medication you take. The most common side effects of GLP-1 medications are digestive side effects such as nausea, vomiting, diarrhea, bloating, or constipation. These side effects occur most frequently when starting treatment or when increasing the dose. Side effects generally resolve over time and can often be improved by making adjustments to diet and/or lifestyle. Other side effects such as headache, stomach pain, fatigue, hair thinning/ loss, increased heart rate, muscle loss, or injection site reactions for injectable users have been reported. Less common but more serious side effects such as hypersensitive reactions, low blood sugar, pancreatitis, gall bladder or kidney issues, or vision problems have been reported. GLP-1 medications carry an FDA black box warning about a potential risk for thyroid C-cell tumors and should be avoided in people with a history of personal or family history of medullary thyroid cancer.

    Patients should check with their prescriber if they are taking other medications to help avoid drug interactions as well as before any planned surgeries or procedures as GLP-1 medications may affect anesthesia.

  • Semaglutide (Wegovy), tirzepatide (Zepbound), orforglipron (Foundayo)1-3

    • Contraindications:
      • Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
      • Known serious hypersensitivity reactions to any of the ingredients in the product
    • Warnings and Precautions:
      • Thyroid C-cell tumors have occurred in animal studies; human relevance of this finding has not been determined. Report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia, or dyspnea) to your healthcare provider.
      • Inflammation of the pancreas (pancreatitis): contact your healthcare provider immediately if you have severe pain in your abdomen that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.
      • Acute gallbladder disease or problems including gallstones have occurred. Call your healthcare provider if you have any of the following symptoms of gallbladder disease or complications: pain in your upper stomach (abdomen), yellowing of skin or eyes (jaundice), fever, or clay-colored stool.
      • Hypoglycemia (low blood sugar) risk is increased when using a GLP-1 agonist, especially if also taking medications such as insulin or sulfonylureas. Symptoms of low blood sugar may include dizziness or light-headedness, sweating, shakiness, blurred vision, slurred speech, weakness, anxiety, hunger, headache, irritability or mood changes, confusion or drowsiness, fast heartbeat, feeling jittery.
      • Acute kidney injury: diarrhea, nausea, and vomiting may lead to dehydration which may cause kidney problems such as acute kidney injury and, in rare cases, requiring hemodialysis. It is important that you drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.
      • Gastrointestinal adverse reactions, sometimes severe, have been reported. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
      • Hypersensitivity reactions: stop using the GLP-1 agonist and get medical help right away if you have any symptoms of a serious allergic reaction including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, fainting or feeling dizzy.
      • Increased heart rate may occur, even when at rest. Consider monitoring and tell your healthcare provider if you feel your heart racing or pounding in your chest, lasting for several minutes.
      • Severe gastroparesis or delayed stomach emptying: These medications slow gastric emptying and are not recommended in patients with severe gastroparesis. Inform your healthcare provider if you have severe stomach emptying problems or persistent symptoms such as severe nausea, vomiting, abdominal pain, or inability to tolerate food.
      • Increased risk of pulmonary aspiration (food getting into your lungs) during surgery or other procedures that use anesthesia or deep sedation due to delayed gastric emptying. Tell all your healthcare providers that you are taking this GLP-1 agonist before you are scheduled to have surgery or other procedures.
      • Changes in vision. Tell your healthcare provider if you have changes in vision. A temporary worsening of diabetic retinopathy could occur in patients with type 2 diabetes. (Wegovy, Zepbound, or Foundayo only)
      • Pregnancy and breastfeeding - speak with your provider if you are or plan to be pregnant or breastfeeding, as these GLP-1 agonists should generally not be used during pregnancy or breastfeeding or only be used during pregnancy or breastfeeding if the potential benefit outweighs potential risk to the fetus or breastfed infant.
      • Do not share your medication pen or needles with anyone else. You may give an infection to them or get an infection from them.
    • Common Side Effects
      • Wegovy: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.
      • Zepbound: nausea, diarrhea, vomiting, constipation, abdominal pain, upset stomach, injection site reactions, fatigue, hypersensitivity reactions, belching, hair loss, gastroesophageal reflux disease (GERD).
      • Foundayo: nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, hair loss.
    • Drug or Food Interactions
      • Delayed gastric emptying may impact absorption of other oral medications taken along with GLP-1 agonists.
      • Use of GLP-1 medications may reduce the efficacy of oral hormonal contraceptives (birth control). If you are using oral hormonal contraceptives, add a non-oral contraceptive method or a barrier method of contraception for 4 weeks after starting medication and for 4 weeks after each dose increase for Zepbound (30 days for Foundayo).
      • Increased risk of severe hypoglycemia may occur in patients who are also using insulin or a sulfonylurea . Dose reduction of insulin or sulfonylurea may be required.
      • Be sure to tell your healthcare provider about all the medications you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. GLP-1 agonist medications can change how some medicines work, and other medicines may affect how GLP-1 medications work too.
      • Foundayo only: Do not exceed simvastatin 20 mg once daily when used concomitantly with Foundayo.

How much does this treatment cost?

Walgreens Weight Management is designed to be an affordable, flexible option – no subscription required. Initial visits start at $49, follow-up chat visits and additional video visits (if needed) are $49 each*. Note: Medication cost not included. Eligible patients with commercial insurance may be able to pay as little as $25/month with a manufacturer’s savings card***. Eligible self-pay patients may be able to pay as little as $149/month with a manufacturer’s savings card**. See below for detailed information on pricing available at your preferred pharmacy.

Medicare patients eligible for the Medicare GLP-1 Bridge program can pay $50/ month¶ on select FDA-approved GLP-1s, learn more here.

GLP-1 Medication Pricing with Manufacturer’s Savings Cards (Available at Walgreens Pharmacy)

Wegovy (pill)Wegovy (pen)ZepboundFoundayo
Active IngredientSemaglutide Semaglutide TirzepatideOrforglipron
FormTabletInjectableInjectableTablet
FrequencyOnce daily Once weekly Once weeklyOnce daily
ManufacturerNovo Nordisk Novo NordiskEli LillyEli Lilly
Commercially insured cost with manufacturer's savings card***As little as $25/month†As little as $25/ month††As little as $25/ month‡,‡‡As little as $25/ month§
Self-pay cost with manufacturer's savings card**Starting at $149/month, subsequent doses range from $199-299/mo†Limited time offer: Starting at $199/month for first two months, subsequent doses up to $349/mo††Limited time offer: Starting at $299/month, subsequent doses range from $399-$449/mo‡Limited time offer: Starting at $149/month for two lowest doses, subsequent doses range from $199-$299/mo§

Note: Restrictions and exclusions apply. Prescription based on medical evaluation and not guaranteed. See applicable manufacturer offer terms below.

Already have a prescription? Eligible patients can still use manufacturer savings cards at Walgreens Pharmacies.

Explore more ways we can help

Frequently Asked Questions

GLP-1s

  • Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone in your body that plays a key role in regulating blood sugar, appetite, and digestion. Medications called GLP-1 receptor agonists (also known as GLP-1 medications or GLP-1 agonists, or GLP-1 for short) are designed to mimic this hormone, helping to manage insulin and blood sugar levels, which can result in weight loss and blood sugar regulation.

    Some of the ways they work include reducing the feeling of hunger, making you feel fuller longer, and reducing your blood sugar. Some common examples of GLP-1 agonist medications include semaglutide (Wegovy), tirzepatide (Zepbound), and orforglipron (Foundayo).

  • GLP-1 agonist medications can help manage hunger and blood sugar in several ways, including signaling to the brain to help you feel full sooner, slowing down how quickly food leaves your stomach, helping the pancreas release insulin after meals, and reducing the release of glucagon – a hormone that raises blood sugar. These medications are often prescribed alongside lifestyle changes like diet and exercise, especially for people with obesity or prediabetes who haven’t had success with weight loss on their own.

    The average weight loss with GLP-1 medications can differ based on the specific product and the individual. In certain clinical trials, when compared to a placebo, patients who used Wegovy lost about 15% of their starting body weight in the first 1 to 1.5 years, Zepbound medication users lost 16%, and Foundayo medication users lost 12.4%. Start a Walgreens Weight Management visit to see which GLP-1 agonist may be the right fit for you.

Virtual Care

  • During your Walgreens Weight Management visit, you will fill out a questionnaire to assess whether you meet specific eligibility requirements for a consultation, which include body mass index (BMI) and any weight-related health conditions. After confirming your eligibility, your healthcare provider will work with you to create a personalized treatment plan. For more details about Walgreens Weight Management eligibility, please see “Who is eligible for GLP-1 medications for weight loss?” question above.

  • It’s simple! After completing a short online questionnaire about your health history, if qualified, you’ll start an on-demand video visit with a Walgreens Weight Management provider. They will review your information and if appropriate, will create your treatment plan and prescribe weight loss medication. After your first visit, most follow-up visits will be conducted through chat, where your provider will check your progress and adjust your treatment plan as needed. If you ever need real-time support, like help with side effects, you can always request another on-demand video visit. We’re here to help you every step of the way!

Insurance and pricing

  • You may be able to use insurance to help pay for GLP-1 medications prescribed through Walgreens Weight Management. Walgreens Weight Management now offers prior authorization support on GLP-1s for eligible patients with commercial insurance. Insurance is not currently accepted for Walgreens Weight Management visits at this time. For more details about pricing, please see “How much does this treatment cost?” question above.

    Medicare patients, click here to learn how the Medicare GLP-1 Bridge program can help cover a portion of your GLP-1 medication costs.

Medicare GLP-1 Bridge program

  • The Medicare GLP-1 Bridge program covers select FDA-approved GLP-1 medications approved for weight loss including Wegovy (semaglutide) injection and tablets, the KwikPen formulation of Zepbound (tirzepatide), and Foundayo (orforglipron) tablets.

  • Virtual care makes it easier to get support on your weight loss journey, without the hassle of scheduling appointments, traveling to a doctor’s office, or paying for a subscription. Eligible Medicare beneficiaries can start a virtual Walgreens Medicare Weight Management visit by completing a clinical questionnaire about their medical history and other health information. If you meet the Medicare GLP-1 Bridge Program eligibility criteria, a doctor or nurse practitioner will review your information and connect with you through secure messaging to discuss your goals and develop a personalized treatment plan. Your care plan may include a prescription for a Bridge-covered GLP-1 medication if appropriate, along with ongoing follow-ups with a provider to check your progress and medication tolerance.

    Most patients start with monthly follow-ups for the first few months so their provider can adjust their medication dosage for the best results. Once medication dosage stabilizes, check-ins typically become less frequent – about every 3 months, depending on your provider’s recommendation.

  • If you meet the Medicare GLP-1 Bridge program’s eligibility requirements, your provider can complete the required prior authorization on your behalf. Upon prior authorization approval, eligible Medicare patients can access select FDA-approved GLP-1s for a $50/month¶ copay. Please note, we don’t currently handle insurance for our virtual visits with the clinician, so the medication copayment does not include the clinician visit cost.

Medicare GLP-1 Bridge program

Beginning July 1, 2026 through December 31, 2027, eligible Medicare beneficiaries can access the following FDA-approved GLP-1 medications for weight loss: Wegovy® (injection or tablet), Foundayo® (tablet), and Zepbound® (KwikPen® only) for $50/month¶ through the Medicare GLP-1 Bridge program. Like all medications, these can have side effects. Click here for more information.

Who may be eligible?

You may be eligible for the Medicare GLP-1 Bridge program if:

  • You have Medicare Part D drug coverage, under either a standalone Medicare Drug Plan or a Medicare health plan that includes drug coverage.
  • You’re not eligible to receive a GLP-1 drug through your Medicare drug plan.
  • You don’t have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Your healthcare provider will need to request prior authorization from Medicare on your behalf.
  • You’re at least 18 years of age AND at least one of these is true:
    • You have a Body Mass Index (BMI) of 35 or higher
    • Your BMI is 30 or higher, and you have certain types of heart failure OR high blood pressure that’s hard to control OR chronic kidney disease (stage 3a or above)
    • Your BMI is 27 or higher, and you have prediabetes OR you’ve had a heart attack, stroke or blocked arteries in your legs or arms

Note: BMI (Body Mass Index) is a number your doctor calculates based on your height and weight. Ask your doctor what your BMI is if you don’t know.

Medicare beneficiaries interested in learning whether they qualify for the Medicare GLP-1 Bridge should visit Medicare.gov/glp1bridge Opens in a new tab and talk with their doctor about whether a GLP-1 medication may be right for them.

If one of the GLP-1s covered is right for you, your provider will send a prescription to Walgreens or your pharmacy of choice.

Medicare GLP-1 Bridge program FAQs

  • Coverage depends on the medication, the reason it was prescribed, your medical conditions, and your Medicare plan. Select FDA-approved GLP-1 prescriptions may be covered through Medicare Part D for certain medical conditions, such as Type 2 diabetes or sleep apnea. For weight management, eligible Medicare beneficiaries may qualify for the Medicare GLP-1 Bridge program with a prescription and prior authorization submitted by their healthcare provider. Click here for more details. Opens in a new tab

  • Medicare Part D may cover select FDA-approved GLP-1 prescription medications depending on the diagnosis and your plan’s coverage rules. Your healthcare provider and Medicare plan can help confirm whether your prescription should be covered through Part D or if you may be eligible for the Medicare GLP-1 Bridge program. Click here for more details. Opens in a new tab

  • Medicare Part D coverage for medications prescribed only for weight loss may be limited. However, patients enrolled in a Medicare Part D plan may be eligible for the Medicare GLP-1 Bridge program. The Medicare GLP-1 Bridge program is intended to help eligible Medicare beneficiaries access select FDA-approved GLP-1 prescriptions for weight management. Eligibility must be confirmed by your healthcare provider through a prior authorization process. Click here for more details. Opens in a new tab

References

Disclaimers

*Medication not included. Rx based on medical evaluation.

**Starting $149/month self-pay pricing available on select doses and medications, pricing may be available for a limited time and is subject to change. Visit price not included. Restrictions apply. Prices are medication-, presentation-, and dose-specific; starting-dose prices are not maintenance-dose prices.

***Eligible commercially insured patients with GLP-1 coverage may pay as little as $25/month for the medication with a manufacturer’s savings card. Eligibility, prior authorization and coverage rules apply. Contact your plan for details. Pricing and availability subject to change. Visit price not included. Prices are medication-, presentation-, and dose-specific; out-of-pocket cost may vary over time based on factors such as health plan benefits, deductible status, and eligible for manufacturer savings programs.

¶$50/month copayment covers GLP-1 medication for weight loss through Medicare GLP-1 Bridge program only; healthcare services (including visit costs) are not included. Eligibility, prior authorization and coverage rules apply. Contact your plan or healthcare provider for details.

Please note that the pricing listed is not Walgreens’ usual and customary price.

Walgreens Weight Management is currently available in all U.S. states except AL and LA. For Medicare Bridge patients, Walgreens Weight Management is available in all U.S. states except AL, DC, DE, KS, LA, MS, NM, RI, and WV.

Based on national averages. Actual wait times may vary.

The Medicare GLP-1 Bridge program is a separate program offered by CMS, supported by Walgreens Pharmacy and other pharmacies to help Medicare patients with an existing GLP-1 prescription pay for their GLP-1s. An existing prescription alone may not establish eligibility.

Prescription based on medical evaluation and not guaranteed. Providers include doctors or nurse practitioners. Other restrictions may apply. For side effects, see “Additional Safety Information and Side Effects of GLP-1s” content above.

Walgreens-affiliated medical practices are independently owned and operated by licensed physicians who provide services using the Walgreens virtual care program telehealth platform. For more information about the relationship between Walgreens and the medical practices click here.

Walgreens Health Medical Group California P.C. is a California professional medical corporation utilizing the fictitious name "Walgreens Health Medical Group California P.C." pursuant to Cal. Bus. & Prof. Code § 2415. To view the Fictitious Name Permit click here.

This content references third-party trademarks that are the property of their respective owners. Such references are made for informational purposes only and are not sponsored, authorized, or endorsed by, or otherwise affiliated with, the respective trademark owners.

Please note that a GLP-1 medication may not be appropriate in all patients.

† Novo Nordisk’s Wegovy Pill Savings Offer:
For commercially insured patients with Wegovy tablet coverage: Novo Nordisk is offering Wegovy tablets for as little as $25 for 1-month, 2-month, or 3-month prescription fills to commercially insured patients with Wegovy tablet coverage. Subject to a maximum savings of $100 per month. A 1-month fill refers to 1 bottle of 30 tablets equivalents to a 30-day supply, a 2-month fill refers to 2 bottles of 30 tablets equivalent to a 60-day supply, and a 3-month fill refers to 3 bottles of 30 tablets equivalent to a 90-day supply. This offer is not valid for patients enrolled in federal or state healthcare programs (including Medicare, Medicaid, and TRICARE). Novo Nordisk reserves the right to modify or cancel this savings program without notice at any time. See full terms at WegovyTerms.com.

For patients planning to self-pay: Novo Nordisk is offering Wegovy tablets to eligible self-pay patients for $149 per month for the 1.5 mg dose, $199 per month for the 4 mg dose, and $299 per month for the 9 mg and 25 mg doses. Each one-month fill refers to 1 bottle of 30 tablets equivalent to a 30-day supply. This offer is for self-paying patients only and operates outside of any third-party insurance. Patients agree not to seek or accept reimbursement for any out-of-pocket costs from any third-party. Novo Nordisk reserves the right to modify or cancel this savings program without notice at any time. See full terms at WegovyTerms.com.

†† Novo Nordisk’s Wegovy Injection Savings Offer:
For commercially insured patients with Wegovy injection coverage: Novo Nordisk is offering Wegovy injections for as little as $25 for 1-month, 2-month, or 3-month prescription fills to commercially insured patients with Wegovy injection coverage. Subject to a maximum savings of $100 per month. A 1-month fill refers to 1 box of 4 single-dose prefilled pens equivalent to a 28-day supply, a 2-month fill refers to 2 boxes of 4 single-dose prefilled pens equivalent to a 56-day supply, and a 3-month fill refers to 3 boxes of 4 single-dose prefilled pens equivalent to a 84-day supply. This offer is not valid for patients enrolled in federal or state healthcare programs (including Medicare, Medicaid, and TRICARE). Novo Nordisk reserves the right to modify or cancel this savings without notice at any time. See full terms at WegovyTerms.com.

For patients planning to self-pay: Through December 31, 2026, Novo Nordisk is offering eligible self-pay patients new to Wegovy injections an introductory price of $199 per fill for the first two fills of medication (0.25 mg and 0.5 mg doses only). After the first two fills, the cost of Wegovy injections will be $349 per month for subsequent fills of medication. Each fill equals a 28-day supply, which is equivalent to one month of medication. This offer is for self-paying patients only and operates outside of any third-party insurance. Patients agree not to seek or accept reimbursement for any out-of-pocket costs from any third-party. Novo Nordisk reserves the right to modify or cancel this savings program without notice at any time. See full terms at WegovyTerms.com.

‡ Lilly’s Zepbound Single-Dose Pen Savings Card Program:
For commercially insured patients with Zepbound single-dose pen coverage: Through December 31, 2026, Lilly is offering Zepbound single-dose pens for as little as $25 for 1-month, 2-month, or 3-month prescription fills to commercially insured patients with Zepbound single-dose pen coverage. Subject to a maximum savings of $100 per month. A 1-month supply is defined as 28 days and up to 4 single-dose pens; 2-month supply is defined as 56 days and up to 8 single-dose pens; 3 months is defined as 84 days and up to 12 single-dose pens. Participation in the Program requires a valid patient HIPAA authorization. This offer is not valid for patients enrolled in any federal, state, or government funded healthcare program (including Medicare, Medicaid, and TRICARE). Lilly reserves the right to terminate, rescind, revoke, or amend the savings card eligibility criteria and/or term conditions at any time without notice and for any reason. See full terms at https://zepbound.lilly.com/savings/terms-and-conditions.

‡‡ Lilly’s Zepbound KwikPen Savings Card Program:
For commercially insured patients with Zepbound KwikPen coverage: Lilly is offering Zepbound KwikPens for as little as $25 for 1-month, 2-month, or 3-month prescription fills to commercially insured patients with Zepbound KwikPen coverage. Subject to a maximum savings of $100 per month. A 1-month supply is defined as 28 days and 1 KwikPen; 2-month supply is defined as 56 days and up to 2 KwikPens; 3 months is defined as 84 days and up to 3 KwikPens. Participation in the Program requires a valid patient HIPAA authorization. This offer is not valid for patients enrolled in any federal, state, or government funded healthcare program (including Medicare, Medicaid, and TRICARE). Lilly reserves the right to terminate, rescind, revoke, or amend the savings card eligibility criteria and/or term conditions at any time without notice and for any reason. See full terms at https://zepbound.lilly.com/savings/terms-and-conditions.

For patients planning to self-pay: Through December 31, 2026, Lilly is offering Zepbound KwikPens to eligible self-pay patients for $299 per month for the 2.5 mg dose, $399 per month for the 5 mg dose, and $449 per month for the 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. A 1-month supply is defined as 28 days and 1 KwikPen. New and existing patients will automatically receive the $449 offer on their first purchase of the 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. To continue to be eligible for this offer, patients must complete their refill purchase within 45 days of the delivery/received date of your previous Zepbound KwikPen prescription fill. Card may be used for a maximum of up to 11 prescription fills per calendar year. This offer is for self-paying patients only and operates outside of any third-party insurance. Patients agree not to seek or accept reimbursement for any out-of-pocket costs from any third-party. Lilly reserves the right to terminate, rescind, revoke, or amend the savings card eligibility criteria and/or term conditions at any time without notice and for any reason. See full terms at https://zepbound.lilly.com/savings/terms-and-conditions-kwikpen-self-pay.

§ Lilly’s Foundayo Savings Card Program:
For commercially insured patients with Foundayo coverage: Through December 31, 2026, Lilly is offering Foundayo for as little as $25 for 1-month, 2-month, or 3-month prescription fills to commercially insured patients with Foundayo coverage. Subject to a maximum savings of $100 per month. A 1-month supply is defined as 30 days, a 2-month supply is defined as 60 days, and a 3-month supply is defined as 90 days. Participation in the Program requires a valid patient HIPAA authorization. This offer is not valid for patients enrolled in any federal, state, or government funded healthcare program (including Medicare, Medicaid, and TRICARE). Lilly reserves the right to terminate, rescind, revoke, or amend the savings card eligibility criteria and/or term conditions at any time without notice and for any reason. See full terms at https://foundayo.lilly.com/coverage-savings#commercial-terms.

For patients planning to self-pay: Through December 31, 2026, Lilly is offering eligible self-pay patients both 0.8 mg and 2.5 mg doses of Foundayo medication for $149 per month, 5.5 mg doses for $199 per month, and 9 mg, 14.5 mg, and 17.2 mg doses for $299 per month. Each fill equals a 30-supply, which is equivalent to one month of medication. To continue to be eligible for this offer, patients must complete their refill purchase of Foundayo within 45 days of the delivery/received date of your previous Foundayo prescription fill. Card may be used for a maximum of up to 10 prescription fills per calendar year. This offer is for self-paying patients only and operates outside of any third-party insurance. Patients agree not to seek or accept reimbursement for any out-of-pocket costs from any third-party. Lilly reserves the right to terminate, rescind, revoke, or amend the savings card eligibility criteria and/or term conditions at any time without notice and for any reasons. See full terms at https://foundayo.lilly.com/coverage-savings#self-pay-terms.